Clinical trials: Vomit
Chemotherapy-induced Nausea and Vomiting
A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers
The purpose of this study is to assess the safety and tolerability of single increasing doses of intravenously administered rolapitant in healthy male and female subjects.
- Trial name
- NCT02382666
- Testing
- Rolapitant
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Tesaro, Inc.
Chemotherapy-Induced Nausea and Vomiting
Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting
Brief Summary: A randomized, single administration, double-blind, parallel- group Phase 2 dose finding study to assess the efficacy, tolerability, and safety of TRG in patients with chemotherapy-induced nausea and vomiting (CINV)…
- Trial name
- NCT00787566
- Testing
- Intranasal granisetron
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Shin Nippon Biomedical Laboratories, Ltd.
Chemotherapy Induced Nausea and Vomiting
Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy
The purpose of the proposed study is to provide a clinical approach to chemotherapy induced nausea and vomiting (CINV) prophylaxis in cycle 2 of moderately emetogenic chemotherapy or highly emetogenic chemotherapy for patients…
- Trial name
- NCT06065722
- Testing
- Akynzeo
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Simon Williamson Clinic
Chemotherapy-Induced Nausea and Vomiting
To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.
Compared With Fosaprepitant dimeglumine for Injection and Palonosetron Hydrochloride Injection, to Evaluate the Efficacy and Safety of QLM2010 for Injection for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly…
- Trial name
- NCT07081256
- Testing
- QLM2010 for injection；dexamethasone, fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
- Where
- China
- Volunteers
- 665 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Nausea and Vomiting, Chemotherapy-Induced
Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]
This is a two period study of healthy adult subjects to characterize the effect of the dosing of ketoconazole on the the way the body reacts to a dose of GW679769, and to assess the safety profile of oral casopitant with and…
- Trial name
- NCT00404378
- Testing
- ketoconazole, casopitant 100 mg, Casopitant 50 mg
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vomiting
Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment
The purpose of the study is to evaluate how subjects with mild or moderate kidney problems process or breakdown the study drug GW679769 in their bodies as compared to healthy subjects.
- Trial name
- NCT00358813
- Testing
- Casopitant
- Where
- 3 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chemotherapy-Induced Nausea and Vomiting
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
The primary objective is to evaluate the efficacy of two different doses of IV palonosetron in the prevention of chemotherapy induced nausea and vomiting in MEC and HEC patients through 120 hours after start of chemotherapy in…
- Trial name
- NCT01442376
- Testing
- Palonosetron, Ondansetron
- Where
- 67 sites in United States, Argentina and 14 more
- Volunteers
- 502 people
- Sponsor
- Helsinn Healthcare SA
Post-operative Nausea and Vomiting (PONV)
Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
A randomized, double-blind, placebo-controlled, multi-center phase III study to compare the efficacy and safety of aprepitant injection and placebo in the prevention of post-operative nausea and vomiting (PONV).,
- Trial name
- NCT06543966
- Testing
- Aprepitant Injection
- Volunteers
- 486 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Nausea, Vomiting
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
The purpose of this research study is to determine if the Enterra® Therapy System can decrease nausea and vomiting symptoms and improve the quality of life for patients with chronic nausea, with or without vomiting, that have…
- Trial name
- NAVIGATE (NCT06464926)
- Testing
- Enterra Therapy System
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 148 people
- Sponsor
- Enterra Medical, Inc.
Chemotherapy-Induced Nausea and Vomiting (CINV)
Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)
The purpose of this study is to examine the safety, tolerability, and efficacy of MK0517 to prevent Chemotherapy-Induced Nausea and Vomiting (CINV) associated with Cisplatin chemotherapy.
- Trial name
- EASE (NCT00619359)
- Testing
- Comparator: fosaprepitant dimeglumine, Comparator: Aprepitant, Dexamethasone
- Volunteers
- 2,322 people
- Sponsor
- Merck Sharp & Dohme LLC
Nausea and Vomiting, Chemotherapy-Induced
The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer
The purpose of the study is to evaluate the effect of the study drug (GW679769) on a commonly used chemotherapy drug (docetaxel) which will be given I.V.
- Trial name
- NCT00440128
- Testing
- Docetaxel, Casopitant/Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Oncology
Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients
This pragmatic trial addresses the clinical gap through the generation of evidence on the comparative effectiveness between AKYNZEO® and Standard of Care (SoC, including EMEND®) in the real-life setting
- Trial name
- NCT03831633
- Testing
- Akynzeo, Standard of Care
- Where
- France
- Volunteers
- 426 people
- Sponsor
- VIFORFRANCE
Chemotherapy-Induced Nausea and Vomiting (CINV)
Safety Study of Repeat Doses of SUSTOL in Adults
This is a repeat-dose, single-arm, open-label study that will evaluate the potential impact of subject-reported injection-site reactions (ISRs) on activities of daily living (ADL) in adult subjects with cancer receiving SUSTOL®…
- Trial name
- NCT05434663
- Testing
- SUSTOL
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Heron Therapeutics
Gastroenteritis
A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis
The purpose of this study is to demonstrate that domperidone suspension plus oral rehydration therapy (ORT) is more effective than placebo plus ORT at reducing the symptoms of vomiting associated with acute gastroenteritis (AG)…
- Trial name
- NCT02699385
- Testing
- Oral Rehydration Therapy, Domperidone
- Where
- 29 sites in Austria, Belgium and 4 more
- Volunteers
- 10 people
- Sponsor
- Janssen-Cilag International NV
Nausea and Vomiting, Chemotherapy-Induced
The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects
This A Three-Part Drug-Drug Interaction Study To Evaluate Effects of Casopitant On Dolasetron, Granisetron or Rosiglitazone When Co-Administered in Healthy Adults
- Trial name
- NCT00511823
- Testing
- casopitant, dolasetron, granisetron
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline